Healthcare Professionals
Adapta
Pacing System for Bradyarrhythmia Management
You just clicked a link to go to another website. If you continue, you may go to a site run by someone else.
We do not review or control the content on non-Medtronic sites, and we are not responsible for any business dealings or transactions you have there. Your use of the other site is subject to the terms of use and privacy statement on that site.
It is possible that some of the products on the other site are not approved in your region or country.
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
The content of this website is exclusively reserved for Healthcare Professionals in countries with applicable health authority product registrations, except those practicing in France as some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011, article 34.
Click “OK” to confirm you are a Healthcare Professional.
Healthcare Professionals
Pacing System for Bradyarrhythmia Management
The Adapta™ pacemaker models combine physiologic pacing with automaticity. Adapta DR is the first pacemaker with Managed Ventricular Pacing (MVP™) technology, which reduces unnecessary right ventricular pacing by 99%.1 Reducing unnecessary ventricular pacing has been shown to improve clinical outcomes by reducing the risks of atrial fibrillation (AF)2-5 and heart failure hospitalisation (HFH).2,5
Visit the MRI Surescan page to find more information on how to verify, program and safely scan a pacemaker with MRI SureScan Technology.
Device | Model Number |
---|---|
Adapta DR |
ADDR01 |
Adapta DR |
ADDR03 |
Adapta DR |
ADDR06 |
Adapta DR |
ADDRS1 (small) |
Adapta DR |
ADDRL1 (longevity) |
Adapta D |
ADD01 |
Adapta VDD |
ADVDD01 |
Adapta SR |
ADSR01 |
Adapta SR |
ADSR03 |
Adapta SR |
ADSR06 |
Gillis A, Pürerfellner H, Israel C, et al. Reduction of unnecessary ventricular pacing due to the Managed Ventricular Pacing (MVP) mode in pacemaker patients: Benefit for both sinus node disease (SND) and AV block (AVB) indications. Presented at HRS 2005 (Abstract AB21-1).
Anderson HR, et al. Lancet. 1997;350:1210-1216.
Skanes AC, et al. J Am Coll Cardiol. 2001;38:167-172.
Neilsen J, et al. J Am Coll Cardiol. 2003;42:614-623.
Sweeney M, et al. Circulation. 2003;107:2932-2937.